Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Non-Small Cell Lung

Aliases
Non-Small-Cell Lung

181 clinical trials

203 products

32 drugs

Clinical trial
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
SGN-PDL1V
Product
pembrolizumab
Clinical trial
A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib
Status: Active (not recruiting), Estimated PCD: 2016-03-14
Product
Erlotinib
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)
Status:
Product
Capmatinib
Product
LY2875358
Clinical trial
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
Status: Completed, Estimated PCD: 2023-05-31
Product
Durvalumab
Product
SGN-STNV
Clinical trial
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-01
Clinical trial
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)
Status: Completed, Estimated PCD: 2023-08-31
Clinical trial
A Phase I/III, Multi-center, Randomized, Double-blind Study of BAT3306 Plus Chemotherapy Versus Keytruda® Plus Chemotherapy to Evaluate Pharmacokinetics, Efficacy, and Safety in Participants With Stage IV Non-squamous Non-small Cell Lung Cancer.
Status: Not yet recruiting, Estimated PCD: 2027-07-30
Product
EU-Keytruda®
Product
BAT3306
Product
US-Keytruda®
Product
Pemetrexed
Product
Carboplatin
Clinical trial
A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
Status: Active (not recruiting), Estimated PCD: 2023-02-02
Clinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Status: Active (not recruiting), Estimated PCD: 2024-08-23
Clinical trial
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Ribociclib
Clinical trial
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2027-05-05
Product
SGN-ALPV
Clinical trial
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-12-13
Product
cetuximab
Clinical trial
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Pembrolizumab
Product
TAK-676
Clinical trial
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Status: Completed, Estimated PCD: 2022-01-17
Product
KB-GDT-01
Product
MORAb-066
Product
ZN-e4
Clinical trial
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2019-04-01
Product
TRX-221
Product
Cisplatin
Clinical trial
An Open Label, Multicenter, Phase 1/2 Study to Explore the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of TRX-221 in the Treatment of Patients With EGFR Mutant NSCLC Who Progressed Following Prior Therapy With EGFR TKI
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-066, a Humanized Monoclonal Antibody to Human Tissue Factor, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or Non-Small Cell Lung Cancer (Adenocarcinoma) Malignancies
Status: Completed, Estimated PCD: 2016-02-09
Product
treatment
Clinical trial
Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Atezolizumab
Product
Tremelimumab
Product
Paclitaxel
Product
BIO 300
Product
Quaratusugene Ozeplasmid
Clinical trial
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Platinum-Based Chemotherapy
Clinical trial
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Status: Completed, Estimated PCD: 2023-04-12
Product
Lorlatinib
Product
JDQ443
Product
trametinib
Product
BLU-451
Clinical trial
Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)
Status: Active (not recruiting), Estimated PCD: 2024-06-25
Product
osimertinib
Product
Etoposide
Product
Placebo
Product
Bevacizumab
Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
AFM24
Clinical trial
A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Status: Terminated, Estimated PCD: 2023-09-21
Clinical trial
A Phase 1 Study of SGN-EGFRd2 in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
Status: Terminated, Estimated PCD: 2022-12-27
Product
Osimertinib
Product
SGN-EGFRd2
Clinical trial
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Status: Completed, Estimated PCD: 2018-04-30
Product
Efineptakin alfa
Product
afatinib
Clinical trial
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
GNR-051
Clinical trial
A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2019-09-09
Product
Docetaxel
Clinical trial
A Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 (GENERIUM JSC, Russia) in Subjects With Solid Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-11-07
Product
SNK01
Clinical trial
A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2020-12-17
Product
TAK-788
Product
Durvalumab + SoC chemotherapy
Clinical trial
A Double-blind, Placebo Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With MET exon14 Skipping Mutations
Status: Terminated, Estimated PCD: 2022-12-14
Product
Spartalizumab
Clinical trial
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Midazolam
Product
LP-300
Clinical trial
A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
LOXO-260
Product
BLU-945
Product
Lazertinib
Clinical trial
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2021-01-08
Product
Selpercatinib
Product
BI 765049
Clinical trial
A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 765049 and BI 765049 + BI 754091 Administered by Parental Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6
Status: Recruiting, Estimated PCD: 2025-12-23
Product
ezabenlimab
Clinical trial
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Status: Recruiting, Estimated PCD: 2027-08-31
Product
Hyperpolarized xenon MRI
Clinical trial
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Status: Active (not recruiting), Estimated PCD: 2020-03-20
Product
Crizotinib
Clinical trial
KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy
Status: Active (not recruiting), Estimated PCD: 2032-02-13
Product
Boserolimab
Clinical trial
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-06-21
Product
MK-0482
Product
MK-4830
Product
diphenhydramine
Product
acetaminophen
Clinical trial
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Tisotumab vedotin
Product
Nivolumab
Clinical trial
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-26
Clinical trial
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations
Status: Recruiting, Estimated PCD: 2025-03-05
Product
Tyrosine Kinase Inhibitor
Product
Zoledronic Acid
Clinical trial
Development and Analysis of a Sample Bank (Blood, Urine, and Stool) for Cancer Patients, Enabling the Systematic Study of the Effect of Blood, Urinary Tract, and Gut Microbiomes on Response to Treatment
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2027-01-08
Product
TNO155
Product
tislelizumab
Product
Glesatinib
Product
Sitravatinib
Clinical trial
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-11-04
Product
Mocetinostat
Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Sacituzumab Govitecan
Clinical trial
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
Status: Recruiting, Estimated PCD: 2027-01-12
Product
BT8009
Product
AZD7789
Product
SGN-B7H4V
Product
carboplatin
Product
cisplatin
Clinical trial
A PHASE 2, MULTI-CENTER, OPEN-LABEL, DUAL-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORLATINIB (PF-06463922) MONOTHERAPY IN ALK INHIBITOR-TREATED LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA
Status: Active (not recruiting), Estimated PCD: 2020-08-10
Clinical trial
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-05-17
Product
Encorafenib
Product
Sasanlimab
Product
SEA-TGT
Clinical trial
A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
Status: Recruiting, Estimated PCD: 2026-02-20
Product
SGN-CEACAM5C
Product
Binimetinib
Product
Axitinib
Clinical trial
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
Status: Recruiting, Estimated PCD: 2025-07-29
Product
KFA115
Clinical trial
An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2029-03-31
Product
Olaparib
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-07-06
Product
Quaratusugene
Clinical trial
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).
Status: Recruiting, Estimated PCD: 2027-08-17
Clinical trial
Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)
Status: Active (not recruiting), Estimated PCD: 2023-11-07
Product
Datopotamab Deruxtecan
Clinical trial
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Naïve Patients With PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2025-09-17
Clinical trial
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2039-02-13
Product
Vibostolimab
Clinical trial
A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
Status: Terminated, Estimated PCD: 2024-03-20
Product
PF-07284890
Product
Cabozantinib
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2022-09-28
Product
QEQ278
Clinical trial
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Entrectinib
Clinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-21
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-09
Product
Tisotumab Vedotin
Product
DKY709
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-12
Product
PDR001
Product
Pralsetinib
Clinical trial
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Expanded Access of LOXO-260 in Participants With RET Mutant or RET Fusion Tumors Refractory to Prior RET Selective TKI Treatment
Status:
Clinical trial
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Product
HLX04
Product
HLX10
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-03-06
Clinical trial
A Multicenter, Observational Study to Describe the Effectiveness and Treatment Patterns of Dacomitinib Among Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Patients With Brain Metastasis
Status: Not yet recruiting, Estimated PCD: 2026-09-07
Clinical trial
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Product
Sigvotatug Vedotin
Clinical trial
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Product
Repotrectinib
Product
Sotatercept
Product
SEA-CD40
Clinical trial
An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-04-14
Clinical trial
A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung
Status: Completed, Estimated PCD: 2022-04-22
Product
Radium-223 dichloride
Clinical trial
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+
Status: Completed, Estimated PCD: 2017-07-17
Clinical trial
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Completed, Estimated PCD: 2021-12-06
Product
Gemcitabine
Clinical trial
An Expanded Access Protocol for Mobocertinib in Refractory Non-Small Cell Lung Cancer Patients With EGFR exon20 Insertion Mutations
Status:
Clinical trial
An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2020-08-20
Clinical trial
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2021-12-14
Product
CAN04
Clinical trial
An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Status: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Status: Recruiting, Estimated PCD: 2024-03-04
Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2022-12-09
Clinical trial
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors
Status: Completed, Estimated PCD: 2023-03-09
Product
BI 754091
Clinical trial
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-10-25
Clinical trial
A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14).
Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
Status: Completed, Estimated PCD: 2020-09-01
Clinical trial
A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy
Status: Withdrawn, Estimated PCD: 2019-03-01
Product
Bemcentinib
Clinical trial
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation
Status: Recruiting, Estimated PCD: 2025-08-11
Product
CK-301
Product
Dabrafenib
Product
Trametinib
Product
Napabucasin
Clinical trial
A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2017-04-24
Clinical trial
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2022-07-29
Product
Nab-paclitaxel
Product
Bintrafusp alfa
Clinical trial
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-21
Product
tucatinib
Product
trastuzumab
Clinical trial
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Product
Duravalumab
Product
TAK-659
Clinical trial
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2018-11-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)
Status: Terminated, Estimated PCD: 2021-01-08
Product
CC-486
Product
fulvestrant
Clinical trial
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Drug
LY3537982
Clinical trial
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Drug
Pralsetinib
Drug
Gemcitabine
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2033-12-30
Product
Montanide ISA-51 VG
Product
H1299 Cell Lysates
Drug
N-803
Drug
Nab-Paclitaxel
Clinical trial
Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-06-22
Drug
Sitravatinib
Clinical trial
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-02-28
Drug
PD-1 antibody
Drug
Anlotinib
Clinical trial
Uncommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-life Practice in First Line Setting
Status: , Estimated PCD: 2024-09-01
Drug
Osimertinib
Clinical trial
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Status: Recruiting, Estimated PCD: 2026-10-01
Drug
Cisplatin
Clinical trial
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib
Status: Completed, Estimated PCD: 2021-04-06
Product
Bortezomib
Product
NK cells
Clinical trial
Shenlingcao Oral Liquid for Patients With Stage II or IIIA Non-small Cell Lung Cancer Receiving Radical Resection: A Pragmatic, Multicenter Randomized Controlled Trial
Status: Completed, Estimated PCD: 2022-03-14
Product
Shenlingcao
Clinical trial
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab With SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition Of NSCLC
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI Treatment
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Gemcitabine platinum + Erlotinib
Clinical trial
Standard Dosed Alectinib Versus Therapeutic Drug Monitoring Guided Alectinib Dosing
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Alectinib
Clinical trial
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Status: Active (not recruiting), Estimated PCD: 2021-02-24
Product
Topotecan
Product
VX-970
Clinical trial
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2021-11-28
Drug
AN0025
Drug
Tiragolumab
Clinical trial
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
Status: Not yet recruiting, Estimated PCD: 2027-07-13
Product
PF-07934040
Drug
Abraxane
Product
Cetuximab
Drug
fluorouracil
Drug
mFOLFOX6
Drug
Atezolizumab
Clinical trial
Preliminary Survey of Dietary Practices and Nutritional Status of Patients Treated With Radiochemotherapy for Non-small Cell Lung Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Blood sample
Clinical trial
A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-10-01
Clinical trial
A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Radiation Therapy
Product
Ascorbic Acid
Clinical trial
An Open-label, Single-arm, Multicenter, Prospective Study of Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements
Status: Terminated, Estimated PCD: 2021-10-01
Product
Merestinib
Clinical trial
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
Status: Terminated, Estimated PCD: 2021-03-10
Clinical trial
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Status: Completed, Estimated PCD: 2022-12-31
Product
nab-Paclitaxel
Clinical trial
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
Status: Completed, Estimated PCD: 2020-08-10
Clinical trial
A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN
Status: Not yet recruiting, Estimated PCD: 2031-06-15
Product
Zimberelimab
Drug
Sacituzumab govitecan
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Drug
Tocilizumab
Product
Fludarabine
Product
Cyclophosphamide
Product
CISH Inactivated TIL
Product
Aldesleukin
Product
Vinorelbine
Product
Doxil
Product
Taxane
Product
Nab-Paclitaxel
Product
dacomitnib
Product
Disitamab vedotin
Clinical trial
A Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A Compared With Docetaxel in Adult Subjects With Previously Treated Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Status: Recruiting, Estimated PCD: 2026-05-31
Product
docetaxel
Product
Irinotecan
Clinical trial
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Status: Recruiting, Estimated PCD: 2029-02-26
Clinical trial
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2017-04-13
Clinical trial
An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Terminated, Estimated PCD: 2012-09-21
Clinical trial
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-28
Product
SHR-1210
Product
Apatinib
Clinical trial
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
Status: Completed, Estimated PCD: 2019-08-01
Product
G1T38
Product
MORAb-202
Product
RRx-001
Product
Mobocertinib
Product
pemetrexed
Product
BI 754111
Product
BLU-701
Clinical trial
A Single Arm, Phase II Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Pretreated With Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitors
Status: Completed, Estimated PCD: 2022-01-19
Product
Ipilimumab
Product
ADXS11-001
Clinical trial
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status: Recruiting, Estimated PCD: 2021-11-18
Clinical trial
A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)
Status: Active (not recruiting), Estimated PCD: 2024-07-22
Product
M7824
Product
Rhenium
Product
Canakinumab
Clinical trial
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Status: Terminated, Estimated PCD: 2023-06-06
Product
Zirconium-89 Crefmirlimab Berdoxam
Clinical trial
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Status: Recruiting, Estimated PCD: 2009-06-20
Product
AZD8853
Clinical trial
A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Savolitinib
Clinical trial
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2019-01-09
Clinical trial
A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition
Status: Completed, Estimated PCD: 2022-08-31
Product
Nivolumab, Ipilimumab
Clinical trial
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations
Status: Recruiting, Estimated PCD: 2025-03-05
Drug
TKI
Clinical trial
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression: a Prospective, Open-label, Multicenter, Single-arm Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2027-01-31
Product
Denosumab
Clinical trial
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Product
LY4170156
Clinical trial
Preoperative Stereotactic Body Radiotherapy and Platinum-based Doublet Chemotherapy Plus Tislelizumab (Immunotherapy) for Operable Stage II to III EGFR Wild-type Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-25
Product
Tislelizumab
Clinical trial
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC
Status: Recruiting, Estimated PCD: 2026-04-28
Clinical trial
Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Efficacy of Intrathecal Pemetrexed Combined With Tyrosine Kinase Inhibitor for Treating Leptomeningeal Metastasis in EGFR-Mutant NSCLC After Failure of Osimertinib
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Product
Amivantamab
Clinical trial
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
Status: Recruiting, Estimated PCD: 2028-09-01
Product
pembrolizumab/vibostolimab
Drug
durvalumab
Drug
pemetrexed
Drug
etoposide
Drug
carboplatin
Drug
paclitaxel
Clinical trial
Phase I/II Study Assessing Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Primary Lung Cancer With Durvalumab After Definitive Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2020-09-16
Clinical trial
Phase I Clinical Trial Testing the Dose Escalation and Expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration for the Management of Pleural Carcinosis
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cisplatine Teva
Clinical trial
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-08-14
Product
Durvalumab + Doxorubicin + Ifosfamide
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Vemurafenib
Product
Cobimetinib
Clinical trial
Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (PRIMM Study)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
chemotherapy + immune checkpoint inhibitors
Clinical trial
Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
Status: Completed, Estimated PCD: 2022-09-06
Product
Afatinib
Clinical trial
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
Status: Not yet recruiting, Estimated PCD: 2029-11-01
Product
UCB4594
Clinical trial
Bronchial Artery Interventional Therapy and Sequential Radiotherapy in the Treatment of Non-resectable, Non-metastatic Central-type Squamous Lung Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Single-arm Phase 2 Study of Sugemalimab and Chemotherapy as Induction Therapy in Unresectable and Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Sugemalimab
Clinical trial
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Cetrelimab
Product
RO6958688
Drug
Docetaxel
Product
CPI-444
Product
Linagliptin
Clinical trial
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Status: Terminated, Estimated PCD: 2021-10-06
Product
Decitabine
Product
Tetrahydrouridine
Product
Ipatasertib
Product
Evolocumab
Product
XL092
Product
Camonsertib
Clinical trial
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Osimertinib + Bevazizumab
Clinical trial
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC
Status: Terminated, Estimated PCD: 2021-10-22
Product
Platinum Based Chemotherapy
Clinical trial
NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-19
Drug
Varlilumab
Clinical trial
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
Status: Active (not recruiting), Estimated PCD: 2024-12-15
Drug
lenalidomide
Product
Montelukast
Drug
Lazertinib
Clinical trial
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-08-13
Product
DM001
Product
Keytruda
Clinical trial
Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
Status: Completed, Estimated PCD: 2020-06-01
Clinical trial
Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-12-12
Clinical trial
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
Status: Recruiting, Estimated PCD: 2025-06-26
Clinical trial
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
Status: Recruiting, Estimated PCD: 2025-07-03
Product
Doxycycline
Product
Minocycline
Product
Clindamycin
Product
Chlorhexidine
Clinical trial
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative：A Multi-center, Single-arm, Phase II Study
Status: Recruiting, Estimated PCD: 2025-08-31
Drug
Cadonilimab
Clinical trial
A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2
Status: Active (not recruiting), Estimated PCD: 2023-02-07
Drug
pembrolizumab
Clinical trial
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Local Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase II Prospective Immune Neoadjuvant Therapy Study od Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2019-08-28
Clinical trial
A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic，EGFR Mutation-positive NSCLC in Real World Setting
Status: Active (not recruiting), Estimated PCD: 2022-04-26
Clinical trial
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
Status: Recruiting, Estimated PCD: 2026-11-15
Product
Placlitaxel
Clinical trial
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Drug
ipilimumab
Drug
T-VEC
Clinical trial
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2020-01-09
Product
Nintedanib
Clinical trial
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
Status: Active (not recruiting), Estimated PCD: 2023-07-10
Clinical trial
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-02-03
Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-11-01
Product
SGN-MesoC2
Clinical trial
Radiotherapy Dose Escalation Using Intensity-modulated Proton Therapy for Non-small-cell Lung Cancer Patients
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Cisplatin or Carboplatin + Pemetrexed